Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides.
暂无分享,去创建一个
F. Brasseur | M. R. Oliva | T. Boon | F. Garrido | G. Andry | M. López-Nevot | P. Jiménez | F. Ruiz-Cabello | T. Cabrera | N. van Baren | C. Landry | D. Godelaine | M. Marchand | N. Baren | R. Benítez
[1] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[2] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[3] S. Steinberg,et al. Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.
[4] P. Bruggen,et al. T cell defined tumor antigens , 1997 .
[5] F. Oesch,et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.
[6] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[7] F. Garrido,et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.
[8] J. Bodmer,et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. , 1996, Tissue antigens.
[9] N. Cascinelli,et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.
[10] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[11] F. Gudat,et al. Identification and intracellular location of MAGE-3 gene product. , 1995, Cancer research.
[12] Cécile Fizames,et al. The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.
[13] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[14] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[15] M. Maio,et al. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. , 1991, The Journal of clinical investigation.
[16] P. Fisher,et al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. , 1990, Cancer research.
[17] J. Minna,et al. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[18] F. Garrido,et al. HLA class I antigens in human tumors. , 1995, Advances in cancer research.
[19] S. Ferrone,et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.
[20] M. R. Oliva,et al. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. , 1988, Experimental and clinical immunogenetics.